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Abstract The somatostatin upstream enhancer (SMS-UE) is a
highly complex enhancer element. The distal A-element contains
overlapping Pdx1 and Pbx binding sites. However, a point
mutation in the A-element that abolishes both Pdx1 and Pbx
binding does not impair promoter activity. In contrast, a point
mutation that selectively eliminates Pdx1 binding to a proximal
B-element reduces the promoter activity. The B-element
completely overlaps with a Pax6 binding site, the C-element. A
point mutation in the C-element demonstrates that Pax6 binding
is essential for promoter activity. Interestingly, a block mutation
in the A-element reduces both Pax6 binding and promoter
activity. In heterologous cells, Pdx1 potentiated Pax6 mediated
activation of a somatostatin reporter. We conclude that the
L/N-cell-specific activity of the SMS-UE is achieved through
simultaneous binding of Pdx1 and Pax6 to the B- and C-
elements, respectively. Furthermore, the A-element appears to
stabilise Pax6 binding.
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1. Introduction
Cell-speci¢c expression of the glucagon, insulin, somatosta-
tin, and pancreatic polypeptide genes by the four classical cell
types of the islets of Langerhans is regulated at the transcrip-
tional level [1^5]. The promoters of the glucagon, insulin, and
somatostatin genes are composed of a combination of posi-
tively and negatively acting cis-elements [6^12]. Isolated posi-
tively acting cis-elements confer tissue- (islet-) speci¢c or cell-
type- (K-, L-, N-) speci¢c expression [13^17].
Thus, activity of the somatostatin promoter in islet L- and
N-cell lines relies on a composite enhancer element termed the
somatostatin-upstream enhancer (SMS-UE) or TSE-I (tissue-
speci¢c element I) spanning nucleotides 3115 to 375 (see Fig.
1) [11,18^20]. Additional positively acting A/T-rich cis-ele-
ments (TAAT1/TSE-II and TAAT2) further upstream are
also contributing to promoter activity [18,21,22]. The activity
of these elements is dependent on the integrity of a cyclic
AMP response element (CRE) located at position 348 to
341 [11,18]. Additionally, negatively acting factors suppress
activity in non-islet cells [12]. The SMS-UE is a tripartite
element consisting of the subdomains SMS-UE-A, -B, and
-C [11,19]. A so called PISCES motif (pancreatic islet cell
enhancer sequence) is found in the C-element of the SMS-
UE [13]. Interestingly, PISCES motifs are also found in pro-
moter elements within the glucagon and insulin genes [13].
These elements, however, display di¡erent cell-type-speci¢c
activities [20]. Thus, while the glucagon gene G1-element
shows preferential activity in K-cells, the glucagon gene G3-
element has a broad islet cell-speci¢c activity. In contrast, the
insulin gene C2-element and the SMS-UE show L/N-cell-spe-
ci¢c activity [20]. To begin to unravel the mechanism by which
the SMS-UE confers cell-type speci¢city, we analysed the fac-
tors binding to this element in a somatostatin-producing cell
line. We found by antibody supershift experiments that the
major complexes formed on the A-element were produced by
Pdx1 and Pbx proteins. On the B- and C-elements we ob-
served a complex composed of Pdx1 and Pax6 binding simul-
taneously. This complex was also formed by recombinant
Pdx1 and Pax6. By mutational analysis of the SMS-UE, we
found a correlation between formation of the Pdx1-Pax6 com-
plex and promoter activity. Interestingly, small mutations that
abolished Pdx1 and Pbx binding to the A-element did not
reduce promoter activity. However, a block mutation that
also reduced Pax6 binding to the SMS-UE did inhibit pro-
moter activity. Furthermore, Pdx1 enhanced Pax6 mediated
activity of a somatostatin reporter in heterologous cells. To-
gether, these data suggest that the Pdx1-Pax6 complex is func-
tional and required for cell-speci¢c activity of the SMS-UE.
2. Materials and methods
2.1. Plasmids
pCMX-STF1 [23] containing the rat Pdx1 cDNA under control of
the CMV promoter was a gift from J. Leonard, pSG5-Pax6 contain-
ing the quail Pax6 cDNA under control of the SV 40 promoter was a
gift from S. Saule. The somatostatin reporters were constructed by a
multistep procedure. Initially a BglII restriction site was inserted be-
tween the SalI and PstI sites in pCAT-Basic (Promega) creating
pCAT-Basic-B2. A 124 bp BglII-XbaI fragment containing the soma-
tostatin gene sequences from 371 to +53 was isolated from p1.4-CAT
[18] and inserted into BglII and XbaI digested pCAT-Basic-B2, creat-
ing p-71-CAT-Basic-B2. Double stranded oligonucleotides represent-
ing wild-type or mutant somatostatin gene sequences from 372 to
3122 (see Fig. 1) were inserted into BglII digested p-71-CAT-Basic-
B2. The 4X(GAL4-SMS-UE)-CAT reporter was designed using multi-
merised oligonucleotides (see Fig. 6A) inserted in the correct orienta-
tion into the BglII site of the somatostatin minimal reporter construct,
pv2.5-CAT [18]. GAL4-Pdx1, GAL4-Cdx2 fusion constructs were
generated by PCR and inserted in frame into pSG424 [24] using the
BamHI and XbaI cloning sites. The Isl-1 cDNA [25] was inserted into
the EcoRI site of pSG424. GAL4-VP16 has been described previously
[26]. All constructs were veri¢ed by dideoxy cycle sequencing.
2.2. Transfections
Transient transfection assays were done using Lipofectamine (Gib-
co-BRL) according to the manufacturer’s instructions. Brie£y, ap-
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proximately 2.5U105 NIH 3T3 cells were seeded 4^8 h before trans-
fection in a 24-well tissue culture dish (Nunc). 150 ng of reporter
plasmid was cotransfected with 40 ng pGL2-RSV plasmid [27] as an
internal standard. 10 ng of SV40-Pax6 expression plasmid and 1 ng of
CMv-Pdx1 expression plasmid was used. The same amount of empty
expression vectors were used for control. All transfections were ad-
justed to a total of 500 ng DNA per well using pBluescript SKII
(Stratagene). 5^10 min before adding the transfection mix to the cells
they were washed using 1 ml opti-MEM per well. The cells were
incubated overnight in a total volume of 500 Wl of the transfection
mix, after which the same volume of normal culture medium with 20%
serum was added. Cells were cultured for an additional 24 h before
harvesting. Luciferase and CAT activities were measured as previously
described [28]. Quanti¢cation of CAT assays was done using a Phos-
phoImager (Molecular Dynamics). Dual luciferase was measured us-
ing the Dual-Luciferase Reporter Assay System (Promega) and a TD-
20/20 luminometer (Turner Designs). All reporter activities were nor-
malized to the internal standard. For LTC3-som transfections 3 Wl of
lipofectamine was used and the culture period after transfection was
48 h.
2.3. Cell culture and cell extracts
NIH-3T3-B (obtained from R. Schumacher), KTC1.9 [2], and
LTC3-som were cultured in DMEM 1000 mg/l glucose containing
10% fetal calf serum, 100 U penicillin/ml, and 100 Wg/ml streptomycin,
as previously described [29]. LTC3-som cells are a subculture of LTC3
cells [30] which arose spontaneously in our laboratory. It is charac-
terized by somatostatin production in approximately 30^50% of the
cells in the otherwise homogenous insulin-producing cell line (H.V.
Petersen, unpublished result). LTC3-som cells uniformly express Pdx1
and Pax6 (not shown). Nuclear extracts were prepared by the method
of Schreiber et al. [31] except that bu¡er C contained 500 mM KCl
instead of 400 mM NaCl. Furthermore, leupeptin (1 Wg/ml), aprotinin
(1 Wg/ml), 1 mM 4-(2-aminoethyl) benzenesulfonyl £uoride hydro-
chloride (AEBSF), and 1 mM sodium-orthovanadate were included.
The recombinant proteins were produced by transiently transfecting
2U106 NIH 3T3 cells in six-well tissue culture dishes (Nunc) with 3^
6 Wg of the relevant expression plasmid. Whole cell extract was pre-
pared as follows: cells were washed in PBS and lysed in whole cell
extract bu¡er (2.5 mM DDT, 20 mM HEPES pH 7.8, 10 mM KCl,
1 mM MgCl2, 10 mM EGTA, 0.2% Triton X-100 supplemented with
leupeptin (1 Wg/ml), aprotinin (1 Wg/ml), AEBSF (1 mM), and 1 mM
sodium-orthovanadate) using 175 Wl per well. After shaking for 10 min
at room temperature, 33 Wl 2.1 M KCl, 46% glycerol bu¡er was added
and shaking was allowed to proceed for 10 min at room temperature.
The contents of the wells were adjusted to 15% glycerol using a 50%
stock, collected and centrifuged at 20 000Ug for 10 min at 4‡C. The
supernatant was collected and stored at 380‡C. Protein content was
measured using the Bradford assay (Bio-Rad).
2.4. Antisera and electrophoretic mobility shift assays
The 1859 anti-Pdx1 antiserum has been described previously [32].
The bg11 anti-Pax6 antiserum was a gift from S. Saule and has been
described previously [33]. Pbx1 antiserum was purchased from Santa
Cruz, Inc. 5 Wg of nuclear extract was used in standard EMSA. The
reaction bu¡er contained 12.5% glycerol, 30 mM Tris-HCl, 75^100
mM KCl, 20 mM NaCl, 1 mM MgCl, 20^50 Wg/ml poly-dIdC and
20^50 Wg/ml poly-dGdC, 2^4 Wg/ml herring sperm DNA, 0.1% Non-
idet NP-40, 3 mM DTT. For recombinant proteins up to 10 Wg of
whole cell extract was used, and all reactions were adjusted to the
same protein concentration using extracts from untransfected cells.
Antisera were used in a 1/10 dilution in the presence of 15 mM
NaN3 using 2^3 Wl per binding reaction as described previously [28].
Binding reactions were separated on a 5% polyacrylamide gel as pre-
viously described [28]. The gels were dried and analyzed by autora-
diography. Gel images were scanned using Adobe Photoshop 3.0 and
¢gures prepared in Canvas 5.0.2.
3. Results
3.1. Pdx1 and Pbx proteins can bind the isolated SMS-UE-A
element
The SMS-UE of the somatostatin gene contains a Pax6
binding site [20,34] and a Pdx1 binding site [21,23] that have
been shown to confer preferential transcriptional activity in
L- and N-cell lines [20]. As the binding site of the Pax6 paired
domain and Pdx1 binding site only comprise the SMS-UE-B
and -C elements it seemed possible that an SMS-UE-A ele-
ment binding factor contributed to promoter activity along
with Pax6 and Pdx1. We therefore initially identi¢ed the fac-
tors capable of binding to the A-element. The sequence of the
A-element (TTGATTGATTT) resembles the TAAT2 element
(ATGATTAATTA, di¡erences underlined) which is known to
bind Pdx1, either as a monomer or as a complex with one of
the Pbx proteins [22]. By performing EMSA using the A-ele-
ment probe (see Fig. 1) with nuclear extracts isolated from
LTC3-som, an insulin- and somatostatin-producing subculture
of the islet cell line LTC3, we found that one major complex
was formed with LTC3-som extract that was absent from ex-
tracts prepared from the glucagon-producing cell line KTC1.9.
In addition, two minor complexes were present in both
KTC1.9 and LTC3-som extracts (Fig. 2). Addition of antisera
speci¢c for either Pdx1 or Pbx showed that the L-cell-speci¢c
complex was due to Pdx1 binding while the two minor com-
plexes were Pbx immunoreactive (Fig. 2). In contrast to the
TAAT2 element, Pbx/Pdx1 dimer formation was not observed
on the A-element and this was found to be due mainly to the
nucleotide di¡erences at position seven and to a minor degree
also at position 11 between the two sites (F.G. Andersen,
manuscript in preparation). A point mutation at position
three of the Pbx site (M-A1) as well as a block mutation at
positions 4^7 (M-A3) abolished both Pdx1 and Pbx binding to
the A-element (Fig. 2, lanes 10 and 11).
3.2. Pax6 and Pdx1 forms a ternary complex with the
SMS-UE
To test whether a Pax6 and Pdx1 containing complex could
form on the SMS-UE, we performed EMSA using the ABC-
FEBS 21615 2-3-99
Fig. 1. Schematic representation of the rat somatostatin promoter
and synthetic oligonucleotides used in EMSA. Alignment with the
Pax6 paired domain consensus binding site [42] is shown and Pdx1
binding sites are indicated. The Pax6 binding site is indicated by a
hatched box, Pdx1 binding sites as black boxes, Pbx binding sites as
shaded boxes, and the cAMP response element (CRE) as an open
box. The arrow indicates the orientation of the Pax6 binding site.
The sequence of the SMS-UE with Pdx1 binding sites is shown
aligned with the Pax6 paired domain consensus binding site. Muta-
tions deviating from the wild-type rat somatostatin gene sequence
are underlined.
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probe spanning the entire SMS-UE (Fig. 1) in the presence of
LTC3-som nuclear extract. Two major complexes S1 and S2
were observed, however, on shorter exposures (not shown) the
S1 complex was resolved into two complexes of slightly di¡er-
ent mobilities, S1a and S1b (Fig. 3, lane 1). Inclusion of Pax6
or Pdx1 antisera in the binding reaction identi¢ed the S1a
complex as Pdx1 and the S1b complex as Pax6 (Fig. 3, lanes
3^5). The S2 complex contained both Pdx1 and Pax6 (Fig. 3,
lanes 3^5). The Pax6 antiserum failed to completely shift the
S2 complex (Fig. 3, lane 4). This is due to the presence of a
Pdx1 dimer generated by co-occupancy of the A- and B-ele-
ments (see Fig. 2, lane 2 and Fig. 4, lanes 12^14). However,
full length recombinant Pdx1 often failed to generate this
complex, most likely due to insu⁄cient amounts of Pdx1 pro-
duced in the transfected ¢broblasts. The identi¢cation of com-
plex S2 as a Pax6-Pdx1-DNA ternary complex was corrobo-
rated by the ¢nding that recombinant Pdx1 and Pax6 formed
a complex with a mobility identical to the S2 complex (Fig. 3,
lane 9). In agreement with a previous study [28] we observed
that rat Pdx1 migrates slightly faster than mouse Pdx1 (Fig. 3,
compare lanes 1 and 7).
3.3. Sequence requirements for Pax6 and Pdx1 binding to the
SMS-UE: intact A-, B-, and C-elements are required for
optimal Pax6 binding
In order to examine the functional relevance of Pax6 and
Pdx1 binding to the SMS-UE, we introduced a set of muta-
tions in either the A-, B-, or C-elements (see Fig. 1) and tested
the e¡ect of these on binding of recombinant proteins as well
as promoter activity. Plasmids encoding wild type Pax6 and a
truncated version of rat Pdx1 (Pdx1(vN)) deleting most of the
activation domain of Pdx1 [35] were used to generate recombi-
nant proteins in NIH-3T3 cells. Pdx1(vN) was used to ensure
di¡erent migration of Pax6 and Pdx1 monomers. The M-A1
mutation which abolished Pdx1 binding to the A-element (see
Fig. 2) had no e¡ect on Pax6 binding or Pax6-Pdx1-DNA
ternary complex formation (Fig. 4, lanes 7 and 8). In contrast,
the M-A3 mutation, which also abolished Pdx1 binding to the
A-element (see Fig. 2), reduced Pax6 binding as well as Pax6-
Pdx1-DNA complex formation (Fig. 4, lanes 13^16). This was
also clearly seen using LTC3-som nuclear extract (data not
shown). The M-A4 mutation led to a similar reduction in
complex formation as the M-A3 mutation (Fig. 4, lanes 17^
20). Conversely, the M-A2 mutation resulted in increased
Pax6 and Pdx1 monomer, and Pax6-Pdx1-DNA complex for-
mation (Fig. 4, lanes 9^12). The importance of a functional
Pdx1 binding B-element for ternary complex formation was
demonstrated using the M-B1 mutation (Fig. 1). Speci¢c tar-
geting of the Pdx1 consensus site, leaving the Pax6 consensus
una¡ected, resulted in reduced Pdx1 binding and abolishment
of the Pax6-Pdx1-DNA complex, without in£uencing Pax6
monomer formation (Fig. 4, lanes 21^24). The M-A1B1 mu-
tation targeting both the A- and B-element Pdx1 sites resulted
in severe reduction of Pdx1 complex formation, but left Pax6
monomer binding unchanged (Fig. 4, lanes 25^28). The M-B2
mutation abolished the Pax6 complex as well as Pdx1 binding
to the B-element and consequently Pax6-Pdx1-DNA ternary
complex formation (Fig. 4, lanes 29^32). Similarly, when us-
ing LTC3-som nuclear extract no Pax6 immunoreactive com-
plex were observed (data not shown). Finally, the M-C muta-
tion abolished formation of the Pax6 complexes without
a¡ecting Pdx1 binding (Fig. 4, lanes 33^36). The same e¡ect
was seen using LTC3-som nuclear extract (data not shown).
3.4. Mutations that disrupt the Pax6-Pdx1 complex formation
impair promoter activity
To analyse the functional importance of ternary complex
formation we introduced the mutations used in Fig. 2C into a
somatostatin reporter construct (3122/+53) linked to CAT.
We then assayed promoter activity by transiently transfecting
LTC3-som cells with wild type and mutant constructs. The M-
A3, M-B2, and M-C mutations that all a¡ected Pax6 binding
and reduced or abolished ternary complex formation impaired
SMS-UE mediated activity to a level seen with a 371 reporter
construct (Fig. 5A). The M-B1 mutation which compromises
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Fig. 2. Pdx1 and Pbx proteins bind the SMS-UE A-element. 32P-la-
belled A-oligonucleotide (wild-type or mutant as indicated) was in-
cubated with nuclear extract from KTC1.9 or LTC3-som cells and
anti-Pdx1 or anti-Pbx antisera as indicated. Pdx1 and Pbx immu-
noreative complexes are indicated. Note that both mutations (M-A1
and M-A3) abolish binding of both Pdx1 and Pbx proteins.
Fig. 3. Pax6 and Pdx1 forms a ternary complex with the somatosta-
tin upstream enhancer. 32P-labelled ABC-oligonucleotide was incu-
bated with nuclear extract from LTC3-som cells (A) recombinant
Pdx1 and Pax6 (B), and anti-Pdx1 or anti-Pax6 antisera as indi-
cated. The S1a (Pdx1) and S1b (Pax6) complexes are indicated by
arrows. Arrowheads indicates the S2 complex (Pdx1-Pax6-DNA ter-
nary complex). Asterisks indicate non-speci¢c binding. Note that re-
combinant rat Pdx1 migrates slightly faster than Pdx1 from the
mouse cell line LTC3-som.
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Pdx1 binding to the B-element and the M-A1B1 mutation
which a¡ects Pdx1 binding to the A- as well as the B-element,
both without a¡ecting Pax6 binding, resulted in an approxi-
mately 50% reduction in promoter activity (Fig. 5A). The M-
A4 mutation also showed a 50% reduction in promoter activ-
ity, a slightly higher activity than observed for the M-A3
mutation although these two mutations appeared to a¡ect
Pax6 binding similarly. The M-A1 mutation did not a¡ect
promoter activity, suggesting that binding of Pdx1 and Pbx
proteins to the A-element does not contribute to promoter
activity in islet cells. A single mutation, M-A2, resulted in
increased promoter activity (Fig. 5A) which correlated with
increased formation of the Pax6-Pdx1-DNA ternary complex
on this mutant, in addition to increased binding of Pax6 and
Pdx1 monomers.
3.5. Pdx1 potentates Pax6 mediated activation of a
somatostatin reporter
To further test whether Pax6 and Pdx1 were capable of
interacting functionally on the somatostatin promoter we
transfected NIH-3T3 cells with a somatostatin reporter con-
struct in the presence or absence of Pax6 and Pdx1 expression
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Fig. 4. Mutations in the A-, B-, and C-elements of the SMS-UE a¡ects ternary complex formation. 32P-labelled ABC-oligonucleotide (wild-type
or mutant as indicated) was incubated with recombinant N-terminally truncated Pdx1 (Pdx1(vN)) and Pax6 as indicated. Pdx1 and Pax6 mono-
mers are indicated by arrows. Arrowhead indicates the Pdx1-Pax6-DNA ternary complex.
Fig. 5. Pax6 and Pdx1 cooperatively activate the somatostatin promoter. A: Mutations that impair ternary complex formation reduce somato-
statin promoter activity in somatostatin-producing cells. LTC3-som cells were transfected with the indicated wild-type or mutant reporter plas-
mids. Note that the M-A1 mutation that compromises Pdx1 and Pbx binding to the A-element does not reduce promoter activity and that the
M-A3, M-B2, and M-C mutations that a¡ect formation of the Pax6-Pdx1-DNA complex all eliminate the activity of the SMS-UE. The average
of at least three independent experiments is presented, error bars indicate SEM. B: Pdx1 potentiates Pax6 mediated activation of the rat soma-
tostatin promoter. NIH-3T3 cells were transfected with 3122SOM-CAT or 3122SOM(M-C)-CAT and co-transfected with the indicated e¡ector
plasmids or empty expression vectors as control. The average of three independent experiments is presented, error bars indicate S.E.M.
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vectors. Transient transfection analysis revealed that Pdx1
could enhance Pax6 mediated transcriptional activation of
the 3122SOM-CAT reporter construct (Fig. 5B). Mutation
of the Pax6 binding site (3122SOM(M-C)-CAT) reduced
Pax6 mediated activity by 50% and abolished the potentiation
by Pdx1 (Fig. 5B). A 371 somatostatin reporter was only
activated 1.4-fold by Pax6 and Pdx1 did not potentate this
activity (not shown).
3.6. The activation domains of Pdx1 and Cdx2/3 can
co-operate with Pax6 when fused to the GAL4 DNA
binding domain
The activation domain of Pdx1 has been mapped to mainly
three highly conserved sequences within the N-terminal 75
amino acids [35,36]. These sequences are also required by
Pdx1 to synergistically activate insulin-enhancer mediated
transcription together with products of the E2A gene. To
determine whether the activation domain of Pdx1 was re-
quired for transcriptional co-operativity with Pax6, we used
a fusion protein between the GAL4 DNA binding domain
(GAL4-DBD) and the activation domain of Pdx1. As a re-
porter, we constructed a synthetic promoter containing four
copies of the SMS-UE with the B-element replaced by a
GAL4 binding site. The multimerised oligonucleotide was in-
serted in front of the somatostatin minimal promoter in
pv2.5-CAT (Fig. 6A). This reporter could be activated by
Pax6 (Fig. 5B) while the parent vector could not (data not
shown). Activation by GAL4-Pdx1 and transcriptional syn-
ergy between GAL4-Pdx1 and Pax6 was readily observed on
this reporter (Fig. 6B). This activity of the Pdx1 activation
domain was conserved between Xenopus laevis and rat Pdx1
(Fig. 6B). The cooperativity observed between Cdx2/3 and
Pax6 on the glucagon promoter (see accompanying manu-
script) prompted us to examine whether the activation domain
of Cdx2/3 could also synergise with Pax6 on this synthetic
reporter. Use of GAL4-Cdx2/3 fusion constructs revealed
that the N-terminal activation domain of Cdx2/3 [37] was in-
deed capable of cooperating with Pax6 on the synthetic pro-
moter when fused to the GAL4-DBD (Fig. 6B). A GAL4-
VP16 fusion construct was highly active on this reporter but
only capable of modest cooperativity with Pax6 (Fig. 6B).
4. Discussion
Pdx1 has previously been reported to stimulate somatosta-
tin gene transcription [21^23,38]. Three Pdx1 binding sites are
located within approximately 400 bp of the somatostatin 5P-
£anking region [21,23]. Nevertheless, the ¢rst 120 bp of the
promoter is su⁄cient to confer islet cell-speci¢c expression in
transfection assays [11]. In such a construct mutational inac-
tivation of the B-element Pdx1 binding site reduces promoter
activity substantially [11]. Similarly, in a construct including
1400 bp of 5P-£anking sequence, inactivation of the Pdx1 site
in the SMS-UE B-element reduces promoter activity by 70%
[18]. However, as several conserved bases in the Pax6-PD
consensus site are also a¡ected by this mutation it cannot
be excluded that the Pax6 binding is also a¡ected. We now
show that the mutational sensitivity of the C-element is due to
the disruption of the Pax6 binding. Moreover, we show that
this Pax6 binding site is overlapping with a Pdx1 binding site
and that these two sites can be co-occupied. Furthermore,
formation of the Pax6-Pdx1-DNA ternary complex is reduced
when nucleotides outside the Pax6-PD consensus site are mu-
tated (i.e. the M-A3 and M-A4 mutation in the A-element) or
deleted (not shown). The reduced ternary complex formation
correlates with reduced promoter activity. In contrast, a point
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Fig. 6. The activation domains of Cdx2 and Pdx1 synergize e¡ectively with Pax6 when coupled to a heterologous DNA-binding domain. NIH
3T3 cells were transfected with 4X(GAL4-SMS-UE)-CAT and co-transfected with the indicated e¡ector plasmids or empty expression vectors
as control. The average of at least three independent experiments is presented, error bars indicate S.E.M. The numbers above the bars indicate
a cooperative index calculated as the ratio of CAT activity obtained with a GAL4 fusion construct and Pax6 divided by the sum of the levels
obtained by either e¡ector alone. A: Schematic representation of the synthetic 4X(GAL4-SMS-UE) reporter. Four copies of an oligonucleotide
spanning the SMS-UE with the B-element replaced by a GAL4 binding site without disrupting the Pax6 consensus binding site was cloned in
the BglII site a position 371 of the minimal somatostatin promoter construct pv2.5-CAT. B: The N-terminal regions of rat and Xenopus Pdx1
(XlHbox8) as well as Cdx2/3 can cooperate with Pax6. The average normalised activity of each GAL4 fusion construct, in the absence or pres-
ence of co-transfected Pax6, is presented relative to that of cells transfected with the GAL4 DNA-binding domain. A GAL4-VP16 fusion con-
struct included for comparison showed modest cooperativity.
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mutation (M-A1) which reduces Pdx1 and Pbx binding to the
A-element (similar to the M-A3 mutation) has no e¡ect on
promoter activity, suggesting that binding of Pdx1 or Pbx to
the A-element is not required for promoter activity. One pos-
sible explanation for the sensitivity of the A-element to the M-
A3 and M-A4 mutations but not the point mutation (M-A1)
could be that Pax6 contacts this element perhaps through its
homeodomain. This interaction could be selectively a¡ected
by the M-A3 and M-A4 mutations. The increased binding
of Pax6 to the M-A2 mutation and correlating increase in
promoter activity supports that A-element sequences (which
are located outside the paired domain recognition sequence)
are involved in determining the a⁄nity of Pax6 towards the
SMS-UE. The mode of Pax6 binding to the SMS-UE is cur-
rently under investigation. Our data do not support a model
involving binding of Pbx proteins to the A-element. It is,
however, a possibility that binding of Pbx proteins to the
A-element might modulate the activity of the SMS-UE in
other cell types. We have shown that Pax6 mediated activa-
tion of a somatostatin reporter in heterologous cells can be
potentiated by Pdx1. Together, our data suggest that the
SMS-UE comprises a composite Pdx1/Pax6 binding site and
that this contributes to the cell speci¢city of the somatostatin
promoter. In contrast to the insulin and glucagon 5P-£anking
regions which in transgenic mice direct expression to the ap-
propriate cell type [2,3], the somatostatin 5P-£anking region
(34000/+53) drives expression of the non-transforming K1
mutant SV40 T-antigen to L-cells rather than N-cells (M.
Low, R. Ventimiglia, and R.H. Goodman, personal commu-
nication). As N-cells are thought to arise from a Pdx1 positive,
insulin-producing precursor [39,40], we propose that islet-spe-
ci¢c activity of the somatostatin 5P-£anking region gene relies
on co-operation between Pdx1 and Pax6. The expression of
Pdx1 and Pax6 in newly formed N-cells (data not shown, [41])
is consistent with such a model. However, additional mecha-
nisms, possibly mediated by cis-elements upstream of 34000
bp or in the 3P-region, must be required to limit activity to N-
cells.
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